MedTrace Logo

A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03646071 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-04-13

No results posted yet for this study

Summary

RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in patients with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

DRUG

RX108

RX108

Sponsors & Collaborators

  • NeuPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Lyon Gleich, MD · Medpace, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2023-08-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03646071 on ClinicalTrials.gov